AstraZeneca Pharma gets permission to import pharmaceutical formulations

22 Nov 2023 Evaluate

AstraZeneca Pharma India has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for the additional indication of Olaparib film coated tablets of 100mg / 150mg (Lynparza).
Through this approval, Olaparib film coated tablets of 100mg/150mg (Lynparza) in combination with Abiraterone and Prednisone or Prednisolone is indicated for the treatment of adult patients with metastatic castration - resistant prostate cancer.

The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg/150mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any. 

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8252.25 2.55 (0.03%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×